Simplex Trading’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$255K Buy
24,400
+15,900
+187% +$176K ﹤0.01% 4355
2026
Q2
$87.6K Sell
8,500
-31,900
-79% -$241K ﹤0.01% 5717
2026
Q1
$198K Sell
40,400
-18,300
-31% -$100K ﹤0.01% 4310
2025
Q4
$332K Sell
58,700
-26,100
-31% -$140K ﹤0.01% 3712
2025
Q3
$432K Buy
84,800
+8,400
+11% +$48.5K ﹤0.01% 4003
2025
Q2
$386K Buy
76,400
+29,600
+63% +$152K ﹤0.01% 3786
2025
Q1
$264K Sell
46,800
-14,000
-23% -$114K ﹤0.01% 4045
2024
Q4
$527K Buy
60,800
+59,000
+3,278% +$349K ﹤0.01% 3484
2024
Q3
$12K Buy
1,800
+1,600
+800% +$9.9K ﹤0.01% 7049
2024
Q2
$1K Buy
+200
New +$1.5K ﹤0.01% 8427

Other funds holding CADL

Simplex Trading's CADL Position: Q3 2026 in Review

Simplex Trading increased its Candel Therapeutics (CADL) stake by 50% in Q3 2026, buying an estimated $9.8K and bringing the position to 2,631 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6772.

Simplex Trading first reported a position in CADL in Q2 2024 and has held it in 7 quarters since. The position peaked at $158K in Q3 2024. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Simplex Trading held 2,631 shares of Candel Therapeutics worth $27.5K as of Q3 2026.
  • Simplex Trading bought 882 Candel Therapeutics shares in Q3 2026, an estimated $9.8K.
  • Candel Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #6772 holding.
  • Simplex Trading first reported a position in Candel Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Simplex Trading's Candel Therapeutics position peaked at $158K in Q3 2024.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.